Multimodality therapy in stage III non-small cell lung cancer

Martin J. Edelman, David R Gandara, Mack Roach, John R. Benfield

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background. Non-small cell lung cancer commonly presents as locally advanced disease. This category of tumors is heterogeneous. Although some patients clearly benefit from operative management alone, the vast majority (more than 90%) will succumb to their disease within 5 years. In the past decade a large clinical research effort has been undertaken in an attempt to improve on this outcome using a combination of chemotherapy, radiotherapy, and operation. Methods. The English-language literature was reviewed using the headings for lung neoplasms and text words combined modality therapy and multimodality therapy. In addition, the bibliographies of relevant articles were reviewed. Emphasis was placed on prospective randomized trials and large phase II studies. We review the rationale, design, and outcome of these trials, including both operative and nonoperative approaches. Results. Several prospective, randomized trials now demonstrate an advantage to combined modality management over radiotherapy or operation alone when a cisplatin-based chemotherapy regimen is incorporated into the treatment plan. This advantage was seen using both operative and nonoperative approaches. Conclusions. Combined modality therapy offers an improved outcome for patients with stage III non-small cell lung cancer. Whether both operation and radiotherapy are needed for local control, the best sequence of treatment and the optimal chemotherapy regimen remain to be defined.

Original languageEnglish (US)
Pages (from-to)1564-1572
Number of pages9
JournalAnnals of Thoracic Surgery
Volume61
Issue number5
DOIs
StatePublished - May 1996

Fingerprint

Non-Small Cell Lung Carcinoma
Combined Modality Therapy
Radiotherapy
Drug Therapy
Bibliography
Combination Drug Therapy
Cisplatin
Lung Neoplasms
Language
Therapeutics
Research
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Multimodality therapy in stage III non-small cell lung cancer. / Edelman, Martin J.; Gandara, David R; Roach, Mack; Benfield, John R.

In: Annals of Thoracic Surgery, Vol. 61, No. 5, 05.1996, p. 1564-1572.

Research output: Contribution to journalArticle

Edelman, Martin J. ; Gandara, David R ; Roach, Mack ; Benfield, John R. / Multimodality therapy in stage III non-small cell lung cancer. In: Annals of Thoracic Surgery. 1996 ; Vol. 61, No. 5. pp. 1564-1572.
@article{4614efd29bc444d99c7272b0910d66bc,
title = "Multimodality therapy in stage III non-small cell lung cancer",
abstract = "Background. Non-small cell lung cancer commonly presents as locally advanced disease. This category of tumors is heterogeneous. Although some patients clearly benefit from operative management alone, the vast majority (more than 90{\%}) will succumb to their disease within 5 years. In the past decade a large clinical research effort has been undertaken in an attempt to improve on this outcome using a combination of chemotherapy, radiotherapy, and operation. Methods. The English-language literature was reviewed using the headings for lung neoplasms and text words combined modality therapy and multimodality therapy. In addition, the bibliographies of relevant articles were reviewed. Emphasis was placed on prospective randomized trials and large phase II studies. We review the rationale, design, and outcome of these trials, including both operative and nonoperative approaches. Results. Several prospective, randomized trials now demonstrate an advantage to combined modality management over radiotherapy or operation alone when a cisplatin-based chemotherapy regimen is incorporated into the treatment plan. This advantage was seen using both operative and nonoperative approaches. Conclusions. Combined modality therapy offers an improved outcome for patients with stage III non-small cell lung cancer. Whether both operation and radiotherapy are needed for local control, the best sequence of treatment and the optimal chemotherapy regimen remain to be defined.",
author = "Edelman, {Martin J.} and Gandara, {David R} and Mack Roach and Benfield, {John R.}",
year = "1996",
month = "5",
doi = "10.1016/0003-4975(96)00044-6",
language = "English (US)",
volume = "61",
pages = "1564--1572",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Multimodality therapy in stage III non-small cell lung cancer

AU - Edelman, Martin J.

AU - Gandara, David R

AU - Roach, Mack

AU - Benfield, John R.

PY - 1996/5

Y1 - 1996/5

N2 - Background. Non-small cell lung cancer commonly presents as locally advanced disease. This category of tumors is heterogeneous. Although some patients clearly benefit from operative management alone, the vast majority (more than 90%) will succumb to their disease within 5 years. In the past decade a large clinical research effort has been undertaken in an attempt to improve on this outcome using a combination of chemotherapy, radiotherapy, and operation. Methods. The English-language literature was reviewed using the headings for lung neoplasms and text words combined modality therapy and multimodality therapy. In addition, the bibliographies of relevant articles were reviewed. Emphasis was placed on prospective randomized trials and large phase II studies. We review the rationale, design, and outcome of these trials, including both operative and nonoperative approaches. Results. Several prospective, randomized trials now demonstrate an advantage to combined modality management over radiotherapy or operation alone when a cisplatin-based chemotherapy regimen is incorporated into the treatment plan. This advantage was seen using both operative and nonoperative approaches. Conclusions. Combined modality therapy offers an improved outcome for patients with stage III non-small cell lung cancer. Whether both operation and radiotherapy are needed for local control, the best sequence of treatment and the optimal chemotherapy regimen remain to be defined.

AB - Background. Non-small cell lung cancer commonly presents as locally advanced disease. This category of tumors is heterogeneous. Although some patients clearly benefit from operative management alone, the vast majority (more than 90%) will succumb to their disease within 5 years. In the past decade a large clinical research effort has been undertaken in an attempt to improve on this outcome using a combination of chemotherapy, radiotherapy, and operation. Methods. The English-language literature was reviewed using the headings for lung neoplasms and text words combined modality therapy and multimodality therapy. In addition, the bibliographies of relevant articles were reviewed. Emphasis was placed on prospective randomized trials and large phase II studies. We review the rationale, design, and outcome of these trials, including both operative and nonoperative approaches. Results. Several prospective, randomized trials now demonstrate an advantage to combined modality management over radiotherapy or operation alone when a cisplatin-based chemotherapy regimen is incorporated into the treatment plan. This advantage was seen using both operative and nonoperative approaches. Conclusions. Combined modality therapy offers an improved outcome for patients with stage III non-small cell lung cancer. Whether both operation and radiotherapy are needed for local control, the best sequence of treatment and the optimal chemotherapy regimen remain to be defined.

UR - http://www.scopus.com/inward/record.url?scp=0029920798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029920798&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(96)00044-6

DO - 10.1016/0003-4975(96)00044-6

M3 - Article

VL - 61

SP - 1564

EP - 1572

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -